Argent BioPharma Ltd (LSE:MXC, OTC:MGCLF, ASX:RGT) is trading on the OTCQB Venture Market effective May 2 under the ticker symbol MGCLF, which it plans to change.
This transatlantic presence aims to enhance accessibility and liquidity for investors through cross-trading, allowing American transactions in US dollars during market hours.
Trading on the ASX remains unaffected. The OTCQB, a platform for entrepreneurial and development-stage companies, requires up-to-date financial reporting and annual verifications.
"Trading on OTCQB will also, we believe, serve to diversify the share register and increase exposure to a broader range of investors," said managing director Roby Zomer.
In the same announcement, Argent said it had appointed Igor Bluvstein as chief financial officer.
Bluvstein brings over 15 years of experience from various sectors, including e-commerce and biotechnology.
His previous roles include CFO positions at MDD Group and Frutarom Industries, and he holds a BA in accounting and economics from the Open University in Israel, along with CPA certification.